Rafael Holdings Completes Pivotal Phase 3 Study for Niemann-Pick Disease Drug; Topline Data & NDA Expected H2 2026
Summary
Rafael Holdings announced the completion of the last patient visit in its pivotal Phase 3 study for Trappsol® Cyclo™ in Niemann-Pick Disease Type C, with topline data and NDA submission anticipated in the second half of 2026.
Key Events
-
Pivotal Phase 3 Study Completed
The last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C.
-
Key Data & Regulatory Milestones Expected
Topline data from the main study cohort and the submission of a New Drug Application (NDA) to the FDA are both expected in the second half of calendar 2026.
-
Positive Pediatric Sub-study Results
Earlier data from a single-arm pediatric sub-study in patients aged zero to three showed 80% of patients' CGI scores improving or remaining stable, with no serious adverse events related to the study drug.
-
FDA Engagement Confirmed
The company has completed a pre-NDA meeting with the FDA and received acknowledgement for its US Expanded Access Program (EAP).
Analysis
This filing marks a critical advancement for Rafael Holdings' lead candidate, Trappsol® Cyclo™, moving it significantly closer to potential market approval. Completing a pivotal Phase 3 study for a rare, fatal disease like Niemann-Pick Type C is a major milestone, providing a clear path to commercialization. The anticipated topline data and NDA submission in the second half of 2026 create a defined timeline for investors, while the positive pediatric sub-study results offer early confidence in the drug's potential efficacy and safety. This progress is vital for the company, especially given its recent financial challenges, as it positions Rafael Holdings to transition into a commercial-stage biotechnology company.
At the time of this filing, RFL was trading at $1.93 on NYSE in the Life Sciences sector, with a market capitalization of approximately $100.4M. The 52-week trading range was $1.12 to $3.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.